<?xml version="1.0" encoding="UTF-8"?>
<svg height="668.521" width="532.49210214" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <text svg_rhmargin="102.103" x="76.272,81.588,85.127,89.558,92.802,95.902,99.003,102.103" y="21.089000000000055" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:7.97px;font-style:italic;font-weight:normal;">Cancers </text>
  <text x="104.096,108.081,112.066,116.051" y="21.089000000000055" svg_rhmargin="120.036" style="fill:#000000;font-family:DPYECX+URWPalladioL-Bold;font-size:7.97px;font-style:NORMAL;font-weight:BOLD;">2019</text>
  <text svg_rhmargin="122.029" x="120.036,122.029" y="21.089000000000055" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:7.97px;font-style:NORMAL;font-weight:normal;">, </text>
  <text x="124.021,128.006" y="21.089000000000055" svg_rhmargin="131.991" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:7.97px;font-style:italic;font-weight:normal;">11</text>
  <text x="131.991,133.984,135.976,139.961,143.94600000000003,495.794,499.779,501.772,506.123,508.777,510.77,514.755" y="21.089000000000055" svg_rhmargin="518.74" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:7.97px;font-style:NORMAL;font-weight:normal;">, 47 5 of 27</text>
  <text x="76.535,81.516,84.007,88.988,91.479,94.567,101.212,106.194,110.617,114.493,118.916,122.971,126.288,130.164,134.039,136.809,140.684,144.002,146.771,150.826,154.702,157.192,161.616,164.38600000000002,166.876,172.415,175.733,181.272,186.253,189.023,192.898" y="55.95799999999997" svg_rhmargin="196.773" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:9.96px;font-style:italic;font-weight:normal;">2.2. Characteristics of Studies</text>
  <text x="97.795,103.223,106.065,109.316,112.499,117.927,121.178,124.361,132.504,137.83499999999998,139.797,143.937,147.119,153.007,158.972,161.813,166.49,170.63,173.071,175.131,183.273,186.114,189.297,194.97899999999998,196.942,201.824,203.786,206.969,212.3,215.482,220.364,223.205,225.158,230.489,233.74,235.702,240.584,245.466,250.348,252.31,258.178,263.059,266.242,269.083,273.76,279.442,282.625,286.765,288.727,296.87,301.546,305.217,309.893,311.856,314.698,320.38,324.715,327.556,333.443,339.409,344.085,350.04999999999995,352.013,354.854,360.536,362.499,367.83,373.717,377.573,379.526,383.666,386.849,392.736,398.701,401.542,406.219,410.359,412.79999999999995,415.709,421.694,427.376,432.05199999999996,434.015,439.414,444.296,448.436,451.277,455.61199999999997,457.574,461.909,467.592,472.473,476.33,481.211,485.546,488.729,493.406,497.262,500.104,504.243,507.426,510.267,514.602" y="75.44500000000005" svg_rhmargin="518.742" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">Fifty-two studies, with a total of 997 patients were included in our studies. The basic characteristics</text>
  <text x="76.535,82.083,85.467,89.766,95.873,100.954,104.267,107.224,112.091,118.006,121.318,125.627,129.925,135.006,138.837,143.70499999999998,148.003,152.312,158.226,163.775,172.25,178.164,182.462,185.419,191.333,195.632,200.947,206.028,211.647,214.604,219.472,223.77,228.851,231.392,239.897,245.232,253.707,258.574,264.489,267.801,273.45099999999996,277.75,281.134,286.215,291.296,294.68,298.978,304.628,307.585,313.499,319.708,324.01700000000005,328.305,333.853,337.237,341.536,348.741,356.647,363.435,367.733,373.962,378.261,382.773,387.64,390.597,393.554,397.863,402.161,410.636,415.504,419.335,424.203,428.501,431.458,437.372,441.884,444.841,450.969,457.178,462.045,468.254,470.795,475.54,478.497,484.411,488.923,491.88,498.008,504.217,507.174,513.088" y="88.95500000000004" svg_rhmargin="518.738" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">of patients are shown in Table 1. Twenty (20) kinds of CAR T cells were included, including</text>
  <text x="76.535,83.549,91.246,97.854,101.148,109.884,115.285,121.33,124.209,130.194,134.933,140.97799999999998,143.48,149.54399999999998,152.057,156.45,161.188,164.067,166.946,170.24,174.979,180.924,183.803,189.848,194.587,198.494,207.23,212.176,215.05499999999998,217.558,223.058,226.788,232.189,240.44,243.665,249.423,251.926,255.22,260.166,264.559,267.784,273.185,277.093,279.606,283.335,288.074,292.466,297.205,303.151,306.376,311.777,315.685,318.188,323.777,328.724,332.632,335.51,340.457,346.214,349.439,351.942,355.276,358.61,361.944,364.457,367.751,373.796,381.344,386.844,393.453,399.042,402.376,405.71,409.044,412.338,414.81100000000004,417.314,424.328,432.025,438.63399999999996,441.136,447.20000000000005,449.714,454.106,458.845,461.723,464.602,468.79699999999997,471.3,475.494,481.44,486.179,490.571,493.45,499.435,503.827,506.34,509.635,515.036" y="102.46400000000006" svg_rhmargin="518.944" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">CAR-modiﬁed T cell-epidermal growth factor receptor variant III (EGFRvIII), CAR T cells speciﬁc for</text>
  <text svg_rhmargin="256.035" x="76.535,83.984,91.541,96.423,98.532,101.783,109.232,116.789,121.671,124.922,129.062,134.93,139.606,143.941,146.782,152.689,157.024,159.133,166.055,173.651,180.173,182.272,188.257,191.508,193.949,196.058,199.348,205.314,208.565,213.446,218.328,220.437,224.108,228.785,233.12,237.796,243.664,246.847,252.178,256.034" y="115.97400000000005" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">GD2 (GD2-speciﬁc CAR T), IL-13 receptor </text>
  <text x="258.145" y="115.97400000000005" svg_rhmargin="264.705" style="fill:#000000;font-family:MGUWOX+EURM10;font-size:9.96px;font-style:NORMAL;font-weight:normal;">α</text>
  <text x="264.705,269.587,272.838,279.36,284.036,290.002,292.843,296.524,301.2,305.535,308.718,313.395,319.35999999999996,321.459,328.382,335.977,342.49899999999997,344.608,351.53,359.087,363.969,369.885,371.994,377.97900000000004,380.088,383.339,386.63,392.595,397.477,402.358" y="115.97400000000005" svg_rhmargin="408.88" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">2-Redirected CAR CD8+ T (IL13R</text>
  <text x="408.877" y="115.97400000000005" svg_rhmargin="415.437" style="fill:#000000;font-family:MGUWOX+EURM10;font-size:9.96px;font-style:NORMAL;font-weight:normal;">α</text>
  <text x="415.437,420.319,423.57,427.71,433.577,438.254,442.589,445.43,451.337,455.67199999999997,457.781,464.703,472.26,477.141,483.057,485.167,492.089,499.675,506.197,508.306,514.291,517.542" y="115.97400000000005" svg_rhmargin="519.983" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">2-speciﬁc CD8+ CAR T),</text>
  <text x="76.535,83.74,91.646,98.434,101.106,106.787,110.171,115.038,121.146,124.103,130.312,135.179,139.193,148.166,153.247,156.204,158.876,164.526,168.357,173.906,182.381,185.694,191.60799999999998,194.28,197.664,202.745,207.257,210.57,216.118,220.132,222.805,226.646,231.513,236.025,240.893,247.0,250.303,255.851,259.865,262.538,265.921,273.126,281.032,287.82,290.493,296.173,299.557,305.766,313.52,319.17,325.958,329.342,331.883,334.555,340.469,346.596,355.569,360.65,366.56399999999996,369.237,374.104,380.212,383.169,389.378,394.245,398.259,407.232,412.313,415.27,417.943,423.593,427.434,432.982,441.457,444.77,450.68399999999997,453.357,456.741,461.822,466.333,469.646,475.195,479.209,481.871,485.712,490.58,495.092,499.959,506.066,509.379,514.927" y="129.48299999999995" svg_rhmargin="518.941" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">CAR T-epidermal growth factor receptor (CAR T-EGFR), human epidermal growth factor receptor</text>
  <text x="76.535,81.417,84.668,91.59,99.186,105.70800000000001,107.709,113.694,116.946,125.069,131.034,137.556,142.438,145.689,152.611,160.207,166.72899999999998,168.73,174.715,177.966,180.407,182.409,186.744,191.625,195.482,200.881,206.212,211.894,214.735,219.07000000000002,221.072,225.953,231.636,237.318,242.736,248.702,252.558,257.44,261.58,266.256,268.258,271.548,278.06,281.311,288.234,295.829,302.351,304.353,310.338,312.339,315.591,322.513,330.109,333.399,339.911,343.162,350.084,357.68,364.202,366.204,372.189,375.44,377.881,379.882,386.804,394.4,400.551,405.989,409.241,417.862,422.538,426.678,432.009,435.191,440.874,445.55,448.392,451.233,456.915,458.916,462.168,469.09,476.686,482.837,488.275,491.526,500.147,504.824,508.963,514.294,517.545" y="142.99199999999996" svg_rhmargin="519.986" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">2-CAR T(HER2-CAR T), carbonic anhydrase IX-CAR T (CAIX-CAR T), CART-mesothelin (CART-meso),</text>
  <text x="76.535,81.417,87.099,90.282,93.123,96.374,105.61,111.498,115.832,118.674,124.35600000000001,126.514,131.396,133.543,140.465,148.061,154.583,156.741,162.72600000000003,164.874,168.125,173.007,178.689,181.872,184.713,187.964,197.2,204.796,211.718,216.6,218.758,225.68,233.276,239.798,241.946,247.931,251.182,253.623,255.78,260.115,264.997,268.678,273.013,275.854,281.536,286.867,291.543,300.164,305.564,309.42,314.849,320.179,325.862,328.703,333.03799999999995,335.186,340.067,345.75,348.932,351.774,357.202,361.879,367.56100000000004,369.719,376.641,384.237,390.759,392.907,398.892,401.049,404.3,411.223,417.188,424.784,426.942,433.864,441.46,447.98199999999997,450.13,456.115,459.366,461.80699999999996,463.964,468.846,474.528,477.711,480.552,483.803,489.671,493.342,498.673,502.813,505.995,510.877,514.06" y="156.50199999999995" svg_rhmargin="518.737" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">anti-Mucin 1 CAR T (anti-MUC1 CAR T), carcinoembryonic antigen CAR T (CEA CAR T), anti-prostate</text>
  <text x="76.535,80.844,86.951,91.818,96.33,99.287,105.435,109.947,112.66,121.633,126.501,135.474,141.093,145.107,150.188,156.102,160.97,163.693,168.774,174.688,178.001,180.958,186.608,191.476,197.39,200.103,206.312,211.18,215.488,218.445,224.095,230.009,234.877,238.89100000000002,241.614,248.819,256.725,263.51300000000003,266.226,272.455,275.179,278.563,284.701,290.036,299.649,307.555,310.268,316.477,321.344,325.653,328.61,334.26,340.174,345.042,349.056,351.769,358.974,366.879,373.66700000000003,376.391,382.62,386.004,388.545,391.258,400.231,407.019,415.463,423.369,426.093,433.297,441.203,447.991,450.705,456.93399999999997,459.647,464.159,469.026,471.983,474.941,479.25,481.973,488.181,491.139,494.97,499.837,504.349,507.662,512.529" y="170.01099999999997" svg_rhmargin="518.738" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">speciﬁc membrane antigen designer CAR T (PSMA designer CAR T), mRNA CAR T cells directed</text>
  <text x="76.535,81.616,87.266,92.347,95.304,101.218,105.527,108.84,113.788,118.3,121.684,131.297,136.165,139.47799999999998,144.436,147.82,156.793,163.581,172.026,179.93200000000002,184.881,189.393,192.776,202.39,207.257,210.57,213.954,221.158,229.064,235.852,240.801,247.031,250.414,252.95499999999998,257.904,265.108,273.014,279.802,284.751,290.97999999999996,295.929,300.441,305.309,308.266,311.223,315.53200000000004,320.491,323.803,328.884,332.715,338.365,343.233,346.546,349.503,355.417,361.06699999999995,366.016,369.328,375.456,384.429,389.977,393.819,397.202,402.283,406.592,410.901,416.449,420.961,423.918,428.999,432.312,437.179,443.388,448.337,453.987,456.944,462.594,467.106,472.654,478.761,482.592,488.141,491.454,496.321,499.278,505.192,508.576,513.657" y="183.52099999999996" svg_rhmargin="518.738" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">against c-Met (mRNA c-Met-CAR T), CAR T cells targeting tumor-associated glycoprotein-72</text>
  <text x="76.207,79.458,86.38,93.976,100.127,106.112,110.994,115.875,119.127,121.568,123.823,130.745,138.341,144.863,148.114,154.079,157.331,161.666,166.342,169.183,172.024,174.221,182.842,187.724,190.907,196.794,200.651,205.532,208.715,211.556,216.887,222.569,224.756,229.638,235.32,238.503,241.344,246.773,251.449,257.132,263.117,265.313,268.564,275.487,283.083,289.604,292.856,298.821,305.743,314.979,321.833,327.818,331.069,333.51,335.707,340.589,345.47,348.721,353.603,358.485,363.367,366.618,371.685,377.016,379.857,382.698,385.949,388.79,391.631,397.06,401.736,403.933,407.604,412.281,416.616,421.292,427.16,430.343,435.674,439.53,441.727,446.609,448.806,455.728,463.324,469.846,472.033,478.01800000000003,480.214,483.465,488.347,493.229,498.11,502.992,507.874,513.859" y="197.02999999999997" svg_rhmargin="518.741" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">(CART72), CAR-B-cell maturation antigenT (CAR-BCMAT), 19-28z-Toll-like receptor 2 CAR T (1928zT2</text>
  <text x="76.535,83.74,91.646,98.434,102.021,108.25,111.634,114.175,117.762,124.966,132.832,137.913,142.994,146.581,153.785,161.691,168.479,172.067,177.564,180.105,183.692,190.896,198.762,203.843,208.924,212.308,215.62,220.701,224.532,230.182,235.05,238.363,241.32,247.234,252.88400000000001,256.471,263.676,271.582,278.37,281.957,288.186,291.773,295.157,302.362,310.268,316.69,322.371,325.754,330.835,335.916,339.3,341.841,345.702,352.907,360.772,365.853,370.934,374.318,377.631,382.712,386.553,392.203,397.07,400.383,405.251,411.46,415.047,422.251,430.157,436.945,440.533,446.762,450.349,453.733,460.938,468.803,473.884,478.965,482.349,489.553,497.459,504.247,507.835,514.064,517.448" y="210.539" svg_rhmargin="519.988" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">CAR T), CD19 CAR T, CD30-targeting CAR T (CART-30), CD22-targeted CAR T (CD22-CAR T),</text>
  <text x="76.535,83.74,91.605,96.686,101.767,105.151,112.356,120.261,127.05,130.433,139.406,144.955,151.164,154.121,160.269,165.136,171.345,174.8,181.02900000000002,184.495,187.878,192.959,198.874,202.186,205.143,208.527,215.732,223.597,228.678,233.759,237.214,244.419,252.325,258.747,264.976,268.36,270.901,274.356,281.561,289.426,294.507,299.588,302.972,306.284,311.365,315.206,320.856,325.724,329.037,333.904,340.113,343.568,348.649,353.73,357.114,362.195,367.276,372.357,375.812,383.017,390.922,397.71000000000004,401.176,407.405,410.86,414.244,419.325,424.406,427.79,432.871,437.952,443.033,446.487,453.692,461.598,468.386,471.851,478.081,481.465,484.006,487.46,494.665,502.571,509.35900000000004,512.824" y="224.04899999999998" svg_rhmargin="519.053" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">CD20-CAR-modiﬁed T (anti-CD20 CART), CD19-targeted 19-28z CAR T (19-28z CAR T), CAR T</text>
  <text x="76.535,83.74,88.607,91.564,94.52099999999999,97.956,105.862,111.512,116.593,119.55,125.464,129.773,133.08599999999998,136.52,139.833,145.747,150.615,154.039,160.248,165.116,171.894,175.329,183.234,189.149,192.461,195.418,201.068,205.936,211.85,215.285,218.669,224.878,229.745,236.523,239.958,247.163,255.069,261.85699999999997,265.291,271.521,274.905,277.44599999999997,280.87,290.483,296.031,300.34,303.65299999999996,307.087,312.635,316.019,319.454,325.561,330.642,333.955,336.912,341.78,347.694,351.007,355.31600000000003,358.75,367.225,372.092,375.923,380.791,384.226,387.538,391.369,396.237,401.318,404.631,409.498,415.707,419.142,424.761,430.411,433.846,438.927,445.054,448.367,453.916,456.873,462.421,468.071,473.619,479.747,484.05600000000004,487.49,494.695,502.601,509.389,512.824" y="237.558" svg_rhmargin="519.053" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">Cell Against the LeY Antigen (LeY CAR T). Most of patients were treated by autologous CAR T</text>
  <text x="76.535,81.047,85.914,88.871,91.829,96.137,98.678,103.017,108.565,114.479,117.436,123.08600000000001,127.06,130.372,136.287,140.128,144.995,149.863,153.836,159.943,165.024,168.337,171.294,176.162,182.076,185.389,189.698,193.671,202.146,207.013,210.844,215.712,219.685,222.998,226.829,231.696,236.777,240.09,244.958,251.167,255.14,260.759,266.409,270.382,276.591,282.14,288.054,293.602,297.433,300.817,307.026,311.894,315.908,318.865,324.606,329.474,335.683,339.656,346.861,354.766,361.55400000000003,365.528,371.757,375.73,380.242,385.11,388.067,391.024,395.333,397.874,405.403,413.39,416.703,422.617,427.485,431.499,435.472,438.429,444.343,447.727,453.275,457.289,466.262,471.343,474.656,477.613,483.161,489.075,493.049,498.13,503.749,509.298,515.425" y="251.06799999999998" svg_rhmargin="518.738" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">cells, only three patients were treated by donor-derived CAR T cells. Other information about</text>
  <text x="76.535,79.848,85.762,90.63,93.861,101.066,108.972,115.75999999999999,119.001,125.23,128.462,132.974,137.841,140.799,143.756,148.065,151.296,154.253,158.56199999999998,161.803,166.112,172.026,177.574,186.049,191.963,195.195,198.152,204.06599999999997,207.298,212.612,217.693,223.313,226.27,231.138,234.379,239.46,242.001,245.415,248.372,254.286,258.798,261.755,267.883,274.092,277.049,282.963,288.613,291.854,297.596,302.463,306.975,310.288,315.836,319.85,324.159,326.7,330.114,335.764,340.631,346.546,351.414,354.655,357.967,361.981,367.062,372.977,377.285,383.494,389.622,394.134,397.446,400.403,405.952,411.866,415.097,424.07,428.938,432.251,438.165,443.713,449.922,452.463,455.887,462.116,465.348,469.86,474.727,477.684,480.641,483.873,488.954,493.466,496.778,499.736,505.477,510.558,513.871" y="264.577" svg_rhmargin="518.739" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">the CAR T cells is shown in Table 2, including vectors, gene transduction method, T cell activate</text>
  <text svg_rhmargin="421.012" x="76.535,85.508,90.375,93.688,99.602,105.151,111.36,113.901,117.223,123.452,126.602,131.114,135.982,138.939,141.896,145.046,149.558,155.686,158.643,161.956,168.083,171.914,176.78199999999998,179.942,183.255,186.212,195.185,200.052,202.593,205.906,209.218,214.767,218.079,223.16,226.117,229.268,234.349,240.557,249.53,252.487,258.402,261.359,265.667,268.98,272.994,278.075,281.388,284.345,289.893,295.80699999999996,298.968,305.177,310.725,315.034,319.901,324.21000000000004,327.36,332.441,338.355,344.564,347.714,353.821,358.689,362.703,367.011,369.969,374.277,377.59,382.457,388.372,392.884,397.752,400.901,404.214,407.171,416.144,421.012" y="278.086" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">method, T cell culture time, total administration doses and persistence time </text>
  <text x="424.169,427.068,432.866,435.357,440.986,443.885,449.514" y="278.086" svg_rhmargin="454.954" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">in vivo</text>
  <text x="454.953,457.49399999999997,462.564,470.47,473.63,476.943,482.492,485.804,490.885,493.842,496.993,502.541,505.925,509.075,514.156" y="278.086" svg_rhmargin="519.237" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">. A total of 31</text>
  <text x="76.535,79.786,85.331,91.324,96.101,100.33,102.813,108.258,111.579,114.072,122.877,127.864,130.766,133.668,139.213,145.017,150.003,155.807,160.235,163.137,167.914,172.143,174.625,182.942,187.719,191.479,196.256,198.739,204.832,207.734,212.72,218.265,224.069,229.514,233.742,238.519,244.613,247.106,249.599,252.501,258.305,262.733,265.635,271.648,277.741,280.643,286.447,291.992,294.475,299.462,304.449,306.931,310.182,315.727,321.72,326.497,330.726,333.209,338.654,341.975,344.468,348.696,354.141,357.043,359.945,366.039,368.521,377.327,382.314,385.216,388.118,393.662,399.466,404.453,410.257,414.684,417.586,422.363,426.592,429.075,432.399,437.38,442.361,447.348,452.329,457.31,460.63100000000003,463.114,468.1,473.904,479.998,482.491,487.477,492.464,494.946,498.197,503.742,509.736,514.513" y="291.596" svg_rhmargin="518.741" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">types of malignancies were diagnosed, including 21 types of solid malignancies [14–33] and 10 types</text>
  <text x="76.535,82.083,85.467,88.495,94.41,99.277,108.25,113.331,116.644,122.192,125.149,130.698,136.348,139.305,143.817,146.855,155.828,160.909,163.866,166.823,172.473,178.387,183.468,189.382,193.894,196.851,201.719,206.028,209.056" y="305.105" svg_rhmargin="212.44" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">of hematologic malignancies [</text>
  <text x="212.439,217.42" y="305.105" svg_rhmargin="222.401" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">34</text>
  <text x="222.402" y="305.105" svg_rhmargin="227.483" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="227.483,232.464" y="305.105" svg_rhmargin="237.445" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">65</text>
  <text x="237.445,240.829,243.37,248.084,255.99,264.963,270.512,276.426,282.07599999999996,285.104,288.417,294.331,299.199,308.172,310.713,313.882,318.191,323.739,326.697,329.654,335.863,338.891,347.864,352.945,355.902,358.859,364.509,370.423,375.504,381.418,385.93,388.887,393.755,398.064,401.091,404.049,409.963,414.475,417.432,423.559,429.768,434.636,440.845,443.873,448.385,453.933,456.89,462.439,466.28,471.147,475.659,478.972,484.053,487.01,490.038,494.55,499.631,505.545,510.057,514.924" y="305.105" svg_rhmargin="518.938" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">]. Among them, solid malignancies included colorectal cancer</text>
  <text x="76.207,79.462,86.391,92.919,99.849,103.103,105.54599999999999,108.029,114.0,118.682,122.826,131.456,136.792,142.665,145.51,150.396,154.54,157.726,160.57,164.909,167.392,171.536,180.166,185.052,187.896,190.73999999999998,193.223,196.898,202.234,208.127,213.815,219.786,222.269,226.609,231.29,234.134,236.97799999999998,239.46,242.647,248.54,257.17,262.506,266.366,268.849,272.103,279.668,284.799,291.327,298.257,304.248,307.502,309.945,312.428,318.399,326.55,329.394,335.083,340.51700000000005,342.999,347.143,352.029,355.704,360.044,365.38,374.01,378.897,381.379,384.633,390.605,400.378,405.509,408.763,411.20599999999996,413.689,421.146,427.118,436.363,438.806,441.289,449.919,454.806,457.65,460.494,465.928,471.616,476.502,482.19,485.376,487.859,493.733,496.577,501.258,507.151,511.012,515.898" y="318.615" svg_rhmargin="518.742" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">(CRC), desmoplastic small round cell tumor (DSRCT), Ewing sarcoma (EWS), GBM, malignant pleural</text>
  <text x="76.535,85.332,90.104,94.328,99.768,103.016,108.814,113.586,116.485,119.384,124.824,133.621,138.603,141.093,144.41,153.835,159.852,169.277,172.594,175.085,177.576,182.348,185.596,190.019" y="332.124" svg_rhmargin="192.51" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">mesothelioma (MPM), etc.</text>
  <text x="97.795,106.25,111.117,120.09,125.171,128.484,134.032,136.989,142.538,148.188,151.145,155.657,158.664,167.637,172.718,175.675,178.633,184.283,190.197,195.278,201.192,205.704,208.661,213.528,217.837,220.845,229.32,234.187,238.018,242.886,245.894,254.867,259.948,262.905,268.819,271.776,277.426,280.424,284.936,290.484,296.398,300.91,305.778,311.692,315.005,319.018,324.099,327.412,332.28,338.489,341.496,347.045,352.959,355.967,358.924,364.574,373.547,379.654,385.568,391.117,400.09,405.171,408.178,413.259,419.174,425.383,428.39,431.348,436.215,442.343,447.993,452.86,461.833,464.79,469.871,472.412,475.541,478.499,484.413,488.925,491.882,498.009,504.218,507.175,513.089" y="345.633" svg_rhmargin="518.739" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">Hematologic malignancies were mainly concentrated on lymphoma and leukemia, including</text>
  <text x="76.535,81.486,85.883,91.855,95.083,99.827,102.312,105.194,110.7,119.444,125.396,131.159,136.566,142.042,144.924,149.875,154.074,157.302,160.184,164.581,167.067,169.948,174.692,180.663,186.169,190.913,199.657,202.539,207.49099999999999,209.976,213.273,220.978,227.028,233.079,236.377,238.853,241.348,245.547,251.498,254.38,259.123,264.887,267.768,272.16499999999996,274.651,283.395,288.347,292.08,297.586,300.468,306.231,311.182,314.064,316.55,321.501,326.908,332.672,337.41600000000005,339.901,342.782,348.288,357.033,362.984,368.748,374.155,382.899,387.851,390.336,393.633,398.832,408.2,414.806,420.856,424.154,426.63,429.115,435.067,438.978,441.86,450.604,455.556,459.467,464.97299999999996,467.459,476.203,480.947,486.997,489.879,494.83,499.029,502.257,505.139,510.903,515.854" y="359.143" svg_rhmargin="518.736" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">acute lymphoblastic leukemia (ALL), splenic marginal zone lymphoma (SMZL), primary mediastinal</text>
  <text x="76.535,79.492,84.573,88.404,94.054,98.922,104.236,110.445,113.829,118.341,123.208,126.165,129.122,134.437,137.394,143.044,152.017,158.125,164.039,169.587,178.56,183.641,188.956,192.339,198.477,208.09,214.299,221.504,227.713,231.097,233.638,238.962,244.043,248.555,254.682,257.995,262.863,268.177,277.15,282.8,287.668,290.625,296.173,299.13,305.339,310.654,313.611,318.478,324.606,330.256,335.124,344.096,347.054,352.135,357.449,360.833,368.739,378.352,384.561,387.945,390.486,395.8,404.255,409.803,416.012,421.662,427.312,430.269,436.183,441.498,444.455,450.105,459.078,465.185,471.099,476.648,485.621,490.702,496.016,499.4,507.855,514.064,517.447" y="372.652" svg_rhmargin="519.987" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">large B-cell lymphoma (PMBCL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL),</text>
  <text x="76.535,85.508,90.589,96.503,99.816,102.773,107.64099999999999,110.77,115.282,120.15,123.107,126.064,129.194,132.151,137.801,146.774,152.881,158.795,164.344,173.316,178.397,181.527,184.911,194.524,201.729,207.938,211.322,213.863,216.992,223.201,226.158,229.369,232.743,238.871,243.179,248.047,251.187,254.144,259.225,263.056,268.706,273.574,276.703,282.912,286.042,290.554,295.421,298.378,301.335,304.465,307.422,313.072,322.045,328.153,334.067,339.615,348.588,353.669,357.978,361.107,364.491,372.357,378.566,384.774,391.979,398.188,401.572,404.702,409.569,412.882,417.394,419.935,424.944,431.153,436.021,440.329,443.286,449.495,454.363,458.671,461.212,464.504,469.585,474.666,479.747,482.877,488.984,494.065,497.378,500.335,505.203,511.117,514.43" y="386.161" svg_rhmargin="518.739" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">mantle cell lymphoma (MCL), diffuse large B cell lymphomas (DLBCL) etc. Besides, 878 patients</text>
  <text x="76.535,80.366,85.234,89.745,94.613,97.57,103.311,108.179,114.388,117.274,121.786,127.7,132.567,141.54,147.089,150.402,156.316,161.183,165.197,170.278,176.385,182.035,185.419,191.039,196.12,200.428,205.296,211.505,214.381,217.338,222.988,231.961,238.068,243.982,249.53,255.739,260.607,266.714,269.671,274.539,277.851,280.809,286.357,292.271,295.147,300.766,305.634,309.018,314.566,318.407,323.275,326.151,333.355,341.261,348.04900000000004,350.935,357.164,360.04,363.353,369.267,374.135,378.149,383.23,389.337,393.879,396.42,399.397,404.478,409.559,412.445,418.552,423.633,426.946,429.903,434.771,440.685,443.998,448.307,451.182,457.391,460.348,466.557,469.433,475.347,480.895,484.20799999999997,487.094,490.925,495.793,500.304,505.172,508.129,513.87" y="399.671" svg_rhmargin="518.738" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">received chemotherapy-based lymphodepletion before CAR T therapy, 98 patients did not receive</text>
  <text x="76.535,79.492,85.142,94.115,100.222,106.136,111.685,117.894,122.761,128.869,131.826,136.693,140.006,142.963,148.511,154.426,156.96699999999998,162.189,167.27,173.184,179.393,184.078,189.159,194.23999999999998,198.914,205.021,210.102,213.415,216.372,221.24,227.154,230.467,234.776,239.45,245.659,248.616,254.82500000000002,259.509,265.423,270.972,274.28499999999997,278.959,284.04,289.954,295.604,300.279,303.236,309.15,312.534,318.082,322.096,331.069,336.15,339.463,342.42,347.968,353.882,358.567,363.648,369.267,374.816,380.943,384.256,388.931,391.888,397.538,406.511,412.618,418.532,424.08,430.289,435.157,441.264,444.221,449.089,452.401,455.359,460.907,466.821,469.362,479.015,484.35,487.307,493.222,497.733,502.601,507.275,513.19" y="413.18" svg_rhmargin="518.738" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">lymphodepletion, and 21 patients did not any information about lymphodepletion. Since no</text>
  <text x="76.535,79.414,85.171,88.466,93.867,97.775,106.51,111.457,114.682,117.561,122.962,128.72,131.223,136.624,142.382,144.885,149.277,152.156,155.035,160.793,163.671,168.064,173.01,175.88899999999998,178.392,182.122,186.86,191.055,197.0,202.402,208.16,212.354,217.09300000000002,219.586,227.836,232.783,236.97799999999998,239.48,245.426,249.156,254.557,260.147,263.025,269.07,273.809,279.85400000000004,282.356,285.65,291.052,294.96000000000004,297.462,302.409,307.355,312.302,314.805,320.75,325.697,328.922,331.801,336.539,342.297,345.522,349.717,352.19,354.693,360.094,365.852,368.731,374.23199999999997,376.734,381.68,386.627,391.574,394.076,400.022,404.968,408.193,411.072,415.811,421.568,424.793,428.988,431.491,439.742,444.48,448.21,452.94899999999996,455.451,460.19,463.069,465.948,471.448,474.327,479.798,482.677,487.416,489.918,493.212,498.614,502.522,505.015,508.24,513.997" y="426.69" svg_rhmargin="518.736" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">information on clinical response was provided for 156 patients, only 841 patients were eligible for the</text>
  <text x="76.535,81.245,86.801,91.717,94.579,100.508,105.425,108.63,111.492,116.86,122.583,125.081,130.45,133.724,136.222,139.929,144.639,148.808,154.718,160.087,165.81,169.979,174.68900000000002,177.186,181.071,185.987,189.193,193.903,196.361,199.468,207.118,212.841,218.84900000000002,221.347,225.516,230.226,235.782,240.492,246.215,248.712,251.574,257.297,261.663,264.524,270.453,276.461,281.171,287.179,289.677,293.846,297.052,302.981,308.989,311.841,316.551,320.71999999999997,323.218,329.226,332.087,338.09499999999997,340.593,346.316,351.684,354.89000000000004,357.388,362.757,365.854,369.128,373.838,377.72200000000004,380.22,385.137,390.859,396.32599999999996,398.824,401.686,407.409,410.683,416.052,419.936,428.618,433.535,436.741,439.602,444.971,450.694,453.191,458.108,463.546,468.914,474.844,478.05,480.547,484.913,490.282,498.964,507.647,513.016" y="440.199" svg_rhmargin="518.739" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">evaluation of response rate. And seven included studies did not offer any information about common</text>
  <text x="76.535,80.675,83.516,89.481,94.157,96.55,101.227,104.302,107.553,112.23,116.565,119.748,123.887,126.328,128.74,131.922,137.605,143.492,147.63199999999998,150.024,154.905,159.787,164.669,167.07,172.938,177.82,181.003,183.844,188.521,194.203,197.386,201.52599999999998,203.917,212.06,216.737,220.408,225.08399999999997,227.476,232.153,234.994,237.835,243.264,246.105,251.504,254.345,259.021,261.423,264.675,270.005,273.861,276.254,279.437,285.119,289.795,292.188,297.07,302.752,307.633,310.475,315.903,320.043,322.884,327.024,329.415,334.746,337.99699999999996,340.389,344.724,350.055,358.676,367.297,372.628,378.31,380.702,384.842,387.683,393.649,398.325,400.717,405.394,408.469,411.72,416.397,420.732,423.915,428.055,430.496,433.551,438.98,441.821,447.503,452.385,455.226,458.067,462.392,464.83299999999997,467.245,472.126,477.008,481.89,484.282,490.149,495.031,498.214,501.055,505.732,511.414,514.597" y="453.708" svg_rhmargin="518.737" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">side effects, thus 896 patients were eligible for the analysis of common side effects. Finally, 533 patients</text>
  <text x="76.117,84.426,90.224,95.664,98.154,103.136,107.559,113.357,116.256,121.028,126.657,131.429,137.516,140.007,145.447,151.076,155.848,159.783,164.764,167.663,170.562,173.053,176.809,181.581,185.805,191.793,197.232,203.031,207.255,212.027,214.517,219.499,222.816,226.064,230.836,234.77100000000002,237.262,240.51,244.266,249.038,254.019,257.267,266.064,270.836,276.634,279.882,282.373,290.681,295.454,299.209,303.981,306.472,311.453,314.353,317.252,319.742,322.641,328.44,332.863,335.762,341.77,347.857,352.629,358.716,361.207,364.106,369.904,372.395,375.643,381.441,386.21299999999997,388.703,393.685,399.483,404.464,407.363,412.903,417.127,420.026,424.25,426.741,432.18,435.498,437.988,441.744,446.517,449.416,454.397,460.384,464.609,469.381" y="467.218" svg_rhmargin="471.872" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">who achieved overall response after treatment were all included in the analysis of relapse.</text>
  <text x="76.535,81.516,84.007,88.988,91.479,94.567,103.972,107.847,111.165,115.588,118.906,126.099,131.638,136.062,138.831,143.812,147.688,150.457,154.333,156.824,161.247,164.01700000000002,166.507,174.258,180.903,187.548,190.039,194.462,197.232,199.723,206.368,213.561,220.20600000000002,222.696,228.783,231.274,237.361,242.343,246.218,250.093,254.517,259.498,264.48,266.97,269.74,275.279,277.77,283.857,288.28,291.598,294.367,298.243,303.782,307.099,310.97499999999997,313.466,320.659,323.428,326.746,331.728,334.218,341.969,344.738,347.508,350.277,354.153,357.849,361.724,367.264,370.582,373.072,382.477,386.9,389.669,392.439,397.42,402.96,407.383,412.922,416.977,419.747,423.622" y="490.431" svg_rhmargin="427.497" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:9.96px;font-style:italic;font-weight:normal;">2.3. Meta-Analysis of ORR of CAR T Therapy in Patients with Different Malignancies</text>
  <text x="97.795,103.445,108.993,113.007,116.32,121.97,125.354,131.268,134.225,140.139,145.007,147.954,152.262,155.575,161.703,167.912,170.869,175.736,180.045,182.982" y="509.918" svg_rhmargin="186.366" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">Forty-nine studies [</text>
  <text x="186.371,191.352" y="509.918" svg_rhmargin="196.333" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">14</text>
  <text x="196.333" y="509.918" svg_rhmargin="201.414" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="201.414,206.395" y="509.918" svg_rhmargin="211.376" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">19</text>
  <text x="211.377" y="509.918" svg_rhmargin="213.917" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">,</text>
  <text x="213.917,218.898" y="509.918" svg_rhmargin="223.879" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">21</text>
  <text x="223.88" y="509.918" svg_rhmargin="228.961" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="228.961,233.942" y="509.918" svg_rhmargin="238.923" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">32</text>
  <text x="238.924" y="509.918" svg_rhmargin="241.464" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">,</text>
  <text x="241.464,246.445" y="509.918" svg_rhmargin="251.426" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">34</text>
  <text x="251.427" y="509.918" svg_rhmargin="256.508" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="256.508,261.489" y="509.918" svg_rhmargin="266.47" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">55</text>
  <text x="266.47" y="509.918" svg_rhmargin="269.01" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">,</text>
  <text x="269.011,273.992" y="509.918" svg_rhmargin="278.973" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">57</text>
  <text x="278.973" y="509.918" svg_rhmargin="284.054" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="284.054,289.035" y="509.918" svg_rhmargin="294.016" style="fill:#0875b7;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">65</text>
  <text x="294.017,297.401,300.348,303.305,309.219,313.731,316.688,322.816,329.025,331.982,337.896,343.546,346.493,351.574,356.655,361.736,364.672,370.78,375.861,379.173,382.13,386.998,392.912,396.225,400.53400000000005,403.48,411.955,416.823,420.654,425.522,428.468,433.336,436.293,439.25,444.9,447.857,453.477,456.434,461.302,464.248,467.632,473.181,477.195,480.141,483.454,489.368,494.236,497.173,505.16,511.948" y="509.918" svg_rhmargin="518.736" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">] including 841 patients were eligible for the ORR</text>
  <text x="76.535,81.274,86.863,91.81,94.688,100.654,105.6,108.825,111.704,117.106,122.86399999999999,125.356,128.235,133.99300000000002,136.476,142.421,147.368,150.593,153.472,158.21,163.968,167.193,171.388,173.881,182.131,185.01,188.235,193.99300000000002,196.476,202.521,205.399,208.516,211.81,216.549,220.278,225.017,230.775,234.0,236.493,245.228,250.174,253.053,255.932,261.433,267.19,272.137,277.894,282.287,285.166,289.904,294.099,296.572,299.659,305.723,311.481,316.21999999999997,318.712,326.488,333.097,339.70599999999996,342.188,347.59,350.88399999999996,353.377,360.391,368.088,374.697,377.179,383.243,385.736,388.961,394.719,399.458,403.366,408.312,414.258,419.75899999999996,422.251,425.545,430.947,434.855,437.338,443.283,448.23,451.455,454.334,459.072,464.83,468.055,472.25,474.743,482.993,485.872,489.097,494.85499999999996,497.338,501.532,506.934,509.813,512.692" y="523.427" svg_rhmargin="518.737" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">evaluation in patients with different malignancies. The ORR of CAR T therapy for patients with solid</text>
  <text x="76.535,81.516,87.315,93.402,95.882,101.681,106.453,115.25,120.231,123.479,128.918,131.817,137.257,142.796,145.695,150.119,152.599,161.396,166.378,169.277,172.176,177.715,183.513,188.495,194.293,198.716,201.615,206.388,210.612,213.092,215.991,221.78900000000002,224.26,229.032,234.014,238.437,244.235,246.716,251.139,254.039,256.938,262.736,265.635,270.058,275.04,277.939,280.42,284.644,287.892,293.899,299.986,302.885,307.657,311.881,314.362,318.586,324.385,329.824,338.133,342.905,348.99199999999996,351.473,359.782,362.681,368.768,373.53999999999996,376.021,382.108,385.007,388.145,391.463,396.235,399.991,404.763,410.561,414.984,419.757,423.981,426.472,428.952,432.27,436.025,441.465,450.262,452.743,457.724,460.215,465.196,473.56500000000005,476.045,479.293,484.733,487.213,492.195,497.176,502.157,504.648,509.629,517.998" y="536.937" svg_rhmargin="520.489" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">and hematologic malignancies in each clinical studies showed wide differences, from 0.0% to 100.0%.</text>
  <text x="76.226,82.449,88.358,93.221,95.718,101.261,106.996,111.859,115.869,120.945,123.899,126.853,129.351,134.214,138.518,141.827,144.782,153.746,158.822,162.131,166.994,169.491,175.034,178.415,180.912,188.892,195.673,202.455,204.952,210.028,215.936,222.139,224.636,229.712,234.788,243.316,245.813,250.321,255.864,261.772,267.914,274.117,278.98,284.888,289.395,294.258,296.756,299.71,305.618,308.928,313.79,317.8,323.536,328.612,331.56600000000003,334.064,337.444,344.642,348.063,351.44399999999996,353.941,357.322,361.149,366.692,375.656,378.153,381.463,387.371,392.234,394.731,397.686,403.594,409.797,412.751,418.487,421.441,427.644,433.765,438.841,441.795,444.293,448.597,451.907,458.028,464.231,467.185,472.048,476.352,478.85,481.804,486.10799999999995,488.606,492.91,498.819,504.362,512.828" y="550.446" svg_rhmargin="518.736" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">The overall estimate of ORR and 95% conﬁdence interval (CI) from the individual studies is shown</text>
  <text x="76.535,79.443,85.258,87.747,93.302,96.21,101.766,107.792,111.559,116.345,118.843,123.839,128.836,131.334,134.421,142.735,148.191,157.014,162.47,168.026,172.813,178.628,183.415,186.322,189.58,195.13600000000002,197.634,200.892,205.678,209.915,213.172,217.409,219.897,224.134,230.16,235.715,241.271,246.058,250.294,253.552,258.338,264.44300000000004,266.942,270.199,276.005,281.001,284.258,286.757,290.014,295.83,300.616,304.853,309.639,312.128,316.365,319.622,325.648,331.753,334.661,339.447,343.684,346.182,351.998,356.994,363.09900000000005,365.588,369.824,372.732,378.288,384.104,387.012,393.057,397.494,402.49,408.305,411.562,414.051,419.867,424.653,427.911,432.697,436.464,441.92,447.476,452.262,458.078,462.864,465.772,469.03,474.58599999999996,477.084,480.411" y="563.955" svg_rhmargin="483.778" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">in Figure 2a. Homogeneity tests suggested that these studies had signiﬁcant heterogeneity (I</text>
  <text svg_rhmargin="487.563" x="483.777,487.563" y="563.955" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:7.57px;font-style:NORMAL;font-weight:normal;">2 </text>
  <text x="490.554,496.609,499.098,504.094,509.09,517.484" y="563.955" svg_rhmargin="519.982" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">= 76%,</text>
  <text svg_rhmargin="81.516" x="76.535,81.517" y="577.465" style="fill:#000000;font-family:AKYTAJ+URWPalladioL-Ital;font-size:9.96px;font-style:italic;font-weight:normal;">p </text>
  <text x="84.007,90.045,92.535,97.516,100.007,104.988" y="577.465" svg_rhmargin="109.969" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">&lt; 0.01</text>
  <text x="109.97,113.248,115.709,118.829,124.863,130.591,136.527,140.7,143.161,145.661,148.87,154.598,159.31300000000002,161.813,165.701,170.623,176.352,182.366,187.74,196.431,199.709,204.424,207.515,210.802,215.517,219.887,223.096,225.596,234.288,239.662,245.676,250.391,253.255,255.755,263.964,268.886,273.059,275.56,281.495,285.668,290.383,296.397,298.897,302.106,307.48,309.981,314.351,319.273,322.137,326.507,332.443,335.307,340.228,343.427,348.142,350.642,353.851,359.58,364.295,372.986,375.447,378.567,384.601,390.329,395.044,397.544,402.919,408.48,413.195,417.083,422.004,424.869,427.733,430.233,436.149,441.523,446.897,449.762,454.476,460.49,462.991,470.727,477.302,483.877,486.378,491.752,495.03000000000003,497.53,504.509,512.167" y="577.465" svg_rhmargin="518.742" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">). Thus, the random-effect model was used to calculate them. The overall pooled ORR of CAR</text>
  <text x="76.226,82.455,85.219,88.532,94.446,99.314,103.328,108.409,114.516,120.16600000000001,122.93,126.314,131.862,135.876,138.64,144.747,149.828,153.141,156.098,160.966,166.88,170.193,174.502,177.265,185.74,188.697,192.01,197.92399999999998,200.688,204.997,210.545,213.502,216.46,222.669,225.432,230.513,236.428,242.637,245.4,251.315,256.182,265.155,270.236,273.549,279.097,282.054,287.603,293.253,296.21,300.722,303.486,312.459,317.54,320.497,323.454,329.104,335.018,340.099,346.013,350.525,353.482,358.35,362.65900000000005,365.422,373.897,378.978,383.28700000000003,386.051,391.132,396.213,404.749,407.513,410.897,415.977,421.058,429.594,432.358,439.563,442.988,445.529,448.292,453.373,458.454,463.535,468.616,473.697,482.233,485.617,488.158,492.069,498.278,503.359,507.668,512.535" y="590.9739999999999" svg_rhmargin="518.744" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">T therapy for patients with solid and hematologic malignancies was 56% (95% CI: 46–66%). Based</text>
  <text x="76.535,82.083,87.997,90.65,93.963,99.877,104.74499999999999,107.397,111.238,116.105,120.414,126.541,129.499,132.81199999999998,135.464,141.012,144.396,147.048,151.357,157.484,163.104,168.754,172.585,178.133,184.261,190.368,193.03,198.111,204.026,209.107,212.064,217.714,222.022,224.979,229.288,231.829,234.521,237.834,243.748,248.61599999999999,251.268,259.255,266.043,272.831,275.484,283.959,289.04,293.34900000000005,296.0,300.309,303.266,308.916,314.83,317.787,323.935,328.447,333.528,339.442,342.755,345.712,351.36199999999997,354.025,359.939,362.896,368.546,374.46,379.328,383.342,385.994,389.378,394.926,398.94,401.592,407.7,412.78,416.093,419.05,423.918,429.832,433.145,437.454,440.106,448.581,451.538,454.851,460.765,463.417,469.331,474.199,483.172,488.253,491.565,497.114,500.071,505.619,511.269,514.226" y="604.484" svg_rhmargin="518.738" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">on the result of subgroup analysis, the ORR was signiﬁcantly higher for patients with hematologic</text>
  <text x="76.535,85.508,90.589,93.546,96.503,102.153,108.067,113.148,119.062,123.574,126.531,131.399,135.708,138.929,142.313,147.394,152.475,161.01,163.551,166.965,172.046,177.127,185.663,188.895,196.099,199.524,202.065,205.286,210.367,215.448,220.529,225.609,230.69,239.226,242.60999999999999,245.842,250.354,255.902,264.875,270.982,276.063,279.894,284.762,290.971,294.192,297.505,303.053,306.284,312.392,317.473,320.785,323.742,328.61,334.524,337.837,342.146,345.367,353.842,356.799,360.112,366.026,369.257,373.566,379.114,382.071,385.029,391.238,394.459,403.432,408.513,411.47,414.427,420.077,425.991,431.072,436.986,441.498,444.455,449.323,453.632,456.863,460.247,465.328,470.408,478.944,481.485,484.889,489.97,495.051,503.587,506.818,514.023,517.448" y="617.9929999999999" svg_rhmargin="519.988" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">malignancies (71%, 95% CI: 62–79%) compared to patients with solid malignancies (20%, 95% CI:</text>
  <text x="76.037,81.008,85.98,90.951,95.922,100.894,109.246,112.556,115.042,118.134,124.219,130.006,134.769,137.264,141.012,145.775,149.991,155.986,158.879,162.12,164.606,170.035,173.346,175.832,180.047,186.043,191.541,197.069,200.818,206.246,212.242,218.218,220.703,225.674,231.461,236.432,239.326,244.854,249.069,251.963,256.179,258.664,264.093,267.404,269.889,273.131,278.917,283.67999999999995,286.166,292.141,297.112,300.354,303.247,308.01,313.796,317.038,321.254,323.739,332.031,334.924,338.166,343.953,346.438,352.513,355.824,360.238,365.001,367.894,370.787,373.273,382.053,387.024,389.917,392.811,398.339,404.125,409.097,414.883,419.298,422.191,426.954,431.17,433.655,436.966,442.494,445.388,450.916,456.911,460.659,465.42199999999997,467.908,472.879,478.377,481.688,484.184,488.4,494.186,499.615,507.907,512.67" y="631.502" svg_rhmargin="518.745" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">11–34%). The result of subgroup analysis of the patients with B-cell malignancies (Figure 2b) showed</text>
  <text x="76.535,79.848,85.762,90.843,94.156,97.194,100.507,106.421,111.289,114.337,122.324,129.112,135.9,138.939,144.487,147.87099999999998,150.92,157.027,162.108,165.421,168.378,173.245,179.16,182.472,186.781,189.819,198.294,201.251,204.564,210.47799999999998,213.527,221.433,227.642,233.851,236.392,239.429,247.884,254.093,256.634,259.672,268.116,276.571,282.78000000000003,285.828,290.909,296.824,303.033,306.071,313.276,319.484,325.693,328.742,337.217,342.084,345.915,350.783,353.821,358.902,363.983,372.519,375.568,378.952,384.033,389.114,397.65,400.688,407.893,411.317,413.858,416.906,421.987,427.068,432.149,437.23,442.311,450.847,454.231,456.772,459.952,465.033,470.114,478.65,481.688,485.072,490.153,495.234,503.77,506.818,514.023,517.448" y="645.012" svg_rhmargin="519.988" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">that the ORR of patients with ALL, HL, NHL and CLL were 79% (95% CI: 70–86%), 37% (95% CI:</text>
  <text x="76.535,81.516,86.498,91.479,96.46,101.442,109.81,113.128,115.619,118.109,123.09,128.072,136.441,138.931,142.248,147.23,152.211,160.58,163.07,170.134,173.491,175.98200000000003,178.472,183.454,188.435,193.416,198.397,203.379,211.747,215.06500000000003,217.556,222.537,228.335,234.422,236.913,241.894,246.875,255.244,257.735,261.052,266.033,271.015,279.384,281.874,288.938,292.295,294.786,297.276,302.258,307.239,312.22,317.201,322.183,330.551,333.869,336.36,338.85,342.606,347.378,351.602,357.59,362.362,366.785,370.033,372.932,378.561,383.333,386.232,390.666" y="658.521" svg_rhmargin="393.157" style="fill:#000000;font-family:MSSLTZ+URWPalladioL-Roma;font-size:9.96px;font-style:NORMAL;font-weight:normal;">21–56%), 50% (95% CI: 23–78%) and 68% (95% CI: 45–84%), respectively.</text>
 </g>
</svg>
